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The International Drug Industry: What
the Future Holds for South Africa's
HIV/AIDS Patients
Rosalyn S. Park*
Lack of access to HIV/AIDS drugs is an internationally rec-
ognized problem. There has been growing attention to this issue
since the Trade Related Agreement on Intellectual Property
Rights (TRIPs) strengthened patent protection laws, causing
drug prices worldwide to increase. Poor, developing nations
have been most affected by the patent protection laws and re-
sulting high drug prices, yet these nations also harbor the high-
est number of HIV-positive people. Consequently, the vast ma-
jority of people in need of HIV/AIDS medicines simply cannot
afford them.
South Africa's future with regard to its access to HIV/AIDS
medicines will be influenced by international law, economics,
and politics. TRIPs provides for increased patent protection,
culminating in 2006 when all nations, including the least-
developed, must comply with its provisions. The agreement sets
the patent standards that all nations' laws and national policies
relating to affordable drugs must meet.
Enforcement of these standards comes by way of a world-
wide crusade led by the brand-name pharmaceutical industry.
The brand-name drug industry has an enormous financial inter-
est in profiting from the high prices of their patented drugs.
Weaker patent laws mean competition from producers of generic
drugs and lower drug prices for brand-name companies. Thus,
the industry often pressures many countries to strengthen their
patent laws, sometimes beyond the minimum international
standards. Stronger patent protection means higher drug
* J.D. Candidate, 2002, University of Minnesota Law School; B.S., 1998,
University of Wisconsin-Madison; Intern, 2001, Anti-Slavery International UK.
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prices, and developing countries will ultimately suffer.
Access to HIV/AIDS medicines is becoming an intensely de-
bated international problem while simultaneously becoming a
recognized necessity. South Africa, as the nation with the high-
est number of people living with HIV and AIDS, is the focus of
international attention. Despite the international furor, South
Africa faces barriers that threaten to block its access to afford-
able drugs, including emerging international law, economic
pressure by the pharmaceutical industry, and political strong-
arming by developed nations. Yet, there are other political
measures that provide safeguards for South Africa in its pursuit
of affordable medicines.
This Note examines South Africa's future in accessing af-
fordable HIV/AIDS drugs. The central thesis is that South Af-
rica's future in accessing HIV/AIDS drugs is optimistic because
of legal, political, and general public policy concerns. Part I de-
tails the AIDS crisis, the problem of access to affordable medi-
cines, the generic drugs used to combat HIV/AIDS, TRIPs, and
South Africa's patent-protection laws. Section A of the analysis
in Part II argues that South Africa's laws are valid under inter-
national law and, therefore, safe from legal challenge. Section B
of the analysis in Part II argues that South Africa is further pro-
tected from legal action because of international public policy
concerns. Section B also explains how public relations expand
the pool of potential drug sources for South Africa. Finally, Sec-
tion C of Part II describes how global political influence acts to
increase leverage and improve South Africa's access to essential
medicines. This analysis will show that the future of South Af-
rica looks more promising in terms of obtaining affordable
HIV/AIDS drugs.
I. AN INTERNATIONAL THREAT: COMBATTING THE
DEVASTATING AIDS VIRUS AND THE
PHARMACEUTICAL INDUSTRY
A. THE GLOBAL AIDS CRISIS
Over thirty-six million people are infected and live with the
HIV/AIDS virus.' Ninety-five percent of these people, or 34.3
1. See Special Session of the General Assembly on HIV/AIDS: Report of the
Secretary-General, U.N. GAOR, 55th Sess., Agenda Item 179, 4, U.N. Doc.
A/55/779 (2001) [hereinafter Special Session].
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million individuals, live in developing countries.2 The majority
of these people live in sub-Saharan Africa, South and Southeast
Asia, and Latin America.3 Globally, sub-Saharan Africa is the
most impacted region, facing four million new HIV infections in
1999 alone.4 South Africa has the largest number of HIV/AIDS-
infected people in the world with 4.2 million.5
The impact of AIDS on human life is profound. In 2000,
there were 5.3 million new HIV infections and three million
deaths from AIDS worldwide. 6 Sub-Saharan Africa is at the
center of the crisis, accounting for 3.8 million of the 5.3 million
infections 7 and 2.4 million of the three million deaths.8 As a re-
sult, life expectancy in southern Africa is expected to decline by
fourteen years between 2005 and 2010.9 South Africa suffers an
extremely high morbidity rate as a result of AIDS, with up to
6000 South Africans dying each day. 10
Proper drug treatment can help prolong lifespan and reduce
morbidity. There are several different types of drugs on the
market to help combat AIDS and AIDS-related illnesses. The
drugs most beneficial to people living with HIV/AIDS include:
"antiretrovirals (ARVs) to limit the damage that HIV does to the
immune system and to prevent mother-to-child transmission;""
"anti-infective agents to treat or prevent opportunistic infections
(OIs); " 12 and "palliative drugs to relieve pain, physical and men-
2. See Carmen Pbrez-Casas et al., Setting Objectives: Is There a Political
Will?, CAMPAIGN FOR ACCESS To EFFECTIVE MEDICINES (M6decins Sans Frontibres,
Brussels, Belgium), July 6, 2000, at 5. See also Special Session, supra note 1, % 99.
3. See Report on the Global HIV/AIDS Epidemic, UNAIDS, at 6, U.N. Doc.
UNAIDS/00.13E (2000), available at www.unaids.org/epidemic update/report/ [here-
inafter Report]. 24.5 million people infected with HIV/AIDS live in Sub-Saharan
Africa, 5.6 million live in South and Southeast Asia, 1.3 million live in Latin Amer-
ica, 520,000 live in Western Europe, and 900,000 live in North America. See id.
4. See id. at 8.
5. See id. at 9. India has the second highest number at 3.7 million people. See
id. at 12.
6. See Special Session, supra note 1, 4.
7. See id. 1 5.
8. See id. [11 4, 5.
9. See Statement of the Joint United Nations Programme on HIV/AIDS
(UNAIDS) at the Third WTO Ministerial Conference, UNAIDS, 2, (1999), at
http//:www.unaids.org/publications/documents/health/access/wtostatement.html.
The life expectancy in southern Africa is expected to decline from fifty-nine to forty-
five years of age. See id.
10. See 147 CONG. REC. H995, H995-01 (daily ed. Mar. 20, 2001) (statement of
Rep. Lee).
11. Pdrez-Casas, supra note 2.
12. Id.
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tal discomfort."13 Antiretrovirals are the most important drugs
of the three categories because of their overall success in com-
bating the virus. They reduce the viral load in the bloodstream
to nearly undetectable levels, reduce OIs, prolong life, and
transform HIV/AIDS into a chronic infection requiring only out-
patient care. 14 Antiretrovirals have also been successful in re-
ducing mother-to-child transmission of HIV infection by nearly
seventy percent. 5 One study found that highly active antiretro-
viral therapy reduced AIDS-related mortality in the United
States by seventy-five percent and morbidity by seventy-three
percent. 16 Triple therapy, a combination of three different an-
tiretrovirals, has been the most promising treatment for reduc-
ing levels of mortality among people with AIDS.' 7 Triple ther-
apy's effect of suppressing the replication of the virus results in
decreased Ols, fewer hospitalizations, and most importantly, an
ability to return to the ordinary functions of daily living."8
These wonder drugs have the potential to increase the lon-
gevity and health of millions, but they are beyond the reach of
the majority of people who need them. The high costs of the
pharmaceuticals allow only a small number of people in Africa
to have access to antiretroviral drugs.19 Although palliative and
anti-infective drugs have limited generic versions or no price-
related access problems, 2° most antiretroviral patents are still
valid in the original country and generic versions are difficult to
procure.21  Patent-protected antiretrovirals are exorbitantly
priced, which makes them effectively inaccessible to those in
need until their patents expire and generics can be produced.
13. Id.
14. See Antiretroviral Treatments for HIVIAIDS, WHO, (1997), at
http://www.who.int/inf-fs/en/factl63.html.
15. See id.
16. See B. Hirschel & P. Franciolo, Progress and Problems in the Fight Against
AIDS, 338 NEW ENG. J. MED. 906, 906 (1998).
17. See id. Triple therapy of two Nuclesoside Reverse Transcriptase Inhibitors
(NRTI) + one Protease inhibitors or two NRTIs + one Non Nucleoside Reverse Tran-
scriptase Inhibitor showed reduced mortality among people living with AIDS. See
id. Triple therapy is commonly known as a drug "cocktail."
18. See Guidance Modules on Antiretroviral Treatments: Module 1, Introduc-
tion to Antiretroviral Treatments, UNAIDS & WHO, at 11, U.N. Doc. WHO/ASD/98.1
(1998), available at http: / / www.who.int /HrVAIDS/antiretroviraL
modules/modl.doc.
19. See AIDS in Africa, THE NATION, Aug. 7, 2000, at 4.
20. See P~rez-Casas, supra note 2, at T.1.
21. See id. These antiretrovirals include didanosine (ddI), efavirenz, lami-
vudine (3TC), nevirapine (NVP), stavudine (d4T), zifovudine (AZT), and AZT/3TC
combination. Id.
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As a result, impoverished nations face price-related problems of
access to these vital medicines under patent protection.
The cost of HIV/AIDS drugs varies widely from country to
country. 22 In some cases, the standard United States price for a
drug may be discounted by as much as ninety-eight percent in
other countries. 23 The most important determinant of these dif-
ferent prices between countries is the existence of market mo-
nopolies.24 Market monopolies are created, in part, by national
and international patent laws.25 Patents are the driving force
that encourage the creation of new products and processes in
the market, which benefit the public and stimulate economic
growth.26 Once a nation grants a patent, the patentee has the
"negative" right to prohibit others from "using, offering for sale,
selling, or importing" the invention without the patentee's con-
sent.27 However, no international patent system exists for in-
ventions. Consequently, the inventor must file a patent applica-
tion in every country where protection is desired. 28
The patent compensates pharmaceutical companies for
their research and development (R&D) costs. Drug development
is a risky and expensive process. Synthesizing a drug may take
ten to twelve years, 29 and only one out of 5000 synthesized com-
pounds will make it to the market.30 Since so few drugs advance
to the profit-bearing market, this places more investment bur-
den on the successful drug, in some cases increasing costs by
$350 million.31 Without the protection of patents, pharmaceuti-
cal companies risk losing millions of dollars as companies that
did not have to undertake the costly research and development
produce and sell the same drug at lower costs. 32 Thus, patent
22. See id. at 9. For example, Lamivudine ranges from $0.80, $1.70, $2.40,
$0.50, $1.10, $2.50, $1.60, and $4.50 for Brazil, Colombia, Guatemala, India, South
Africa, Thailand, Uganda and the United States, respectively. Id. at T.2.
23. See Prez-Casas, supra note 2, at T.2.
24. See id.
25. Other factors include tariffs, taxes, price controls, government price nego-
tiations, and price mark-ups. See id.
26. See MICHAEL P. RYAN, KNOWLEDGE DIPLOMACY 26 (1998).
27. P. Boulet et al., Patent Situation of HIVIAIDS-related Drugs in 80 Coun-
tries, UNAIDS & WHO, Jan. 2000, $ 10, at httpJ/www.unaids.org/publications/
documents/health/access/patsit.doc.
28. See id. 8.
29. See RYAN, supra note 26, at 30.
30. See R.G. Halliday, et al., R & D Philosophy and Management in the World's
Leading Pharmaceutical Companies, 2 J. PHARM. MED. 139 (1992).
31. See RYAN, supra note 26, at 30.
32. U.S. pharmaceutical companies' sales to Brazil were $27 million, while un-
authorized sales by Brazilian pharmaceutical companies of the same drugs were $12
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protection serves as a barrier to market entry, providing guar-
anteed profits in the billions of dollars for pharmaceutical com-
panies.
The threat of generic competition still plagues the pharma-
ceutical companies. For example, Brazil can offer some of the
lowest prices for generic products. In Brazil, a generic version of
zidovine sells for one-fourteenth of its price in the United
States.33  Poorer countries buy these drugs from cheaper
sources, such as Brazil, and import them back into their coun-
try, circumventing any national patent laws. Pharmaceutical
companies encounter substantial profit losses on patented drugs
when generic drug producers provide an effective substitute
worldwide. Problems such as this led to the political push for a
new international agreement on intellectual property rights.
B. TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY
RIGHTS ASSIGNMENT
1. In General
The Trade Related Aspects of Intellectual Property Rights
Agreement (TRIPs) is the broadest international intellectual
property agreement because of its expansive coverage and en-
forcement mechanisms. 34 Under TRIPs, Member States must
make patents available for all inventions specifically defined in
TRIPs. 35 Patents are valid for twenty years from the filing
million. See Gerald J. Mossinghoff, Research-Based Pharmaceutical Companies: The
Need for Improved Patent Protection Worldwide, 2 J.L. & TECH. 307, 309 n.6 (1987).
If these drugs had been protected by a Brazilian patent law in 1985, U.S. pharma-
ceutical companies' sales would have increased by nearly 50 percent. See Christo-
pher S. Mayer, The Brazilian Pharmaceutical Industry Goes Walking from Ipanema
to Prosperity: Will the New Intellectual Property Law Spur Domestic Investment?, 12
TEMPLE INT'L & COMP. L.J. 377, 396 (1998).
33. See Pdrez-Casas, supra note 2, at 10.
34. See DANIEL GERvAIS, THE TRIPs AGREEMENT: DRAFTING HISTORY AND
ANALYSIS 3 (1998). TRIPs builds upon the legal foundations of four international
instruments: the Paris Convention protecting industrial property; the Berne Con-
vention protecting literary and artistic works; the Rome Convention protecting per-
formers, broadcasting, and musical works, and; the Treaty on Intellectual Property
protecting integrated circuits. See id. at 26.
35. See Agreement on Trade-Related Aspects of Intellectual Property Rights,
Dec. 15, 1993, 33 I.L.M. 81 (1994) [hereinafter TRIPs]. Members must make patents
available for any inventions that are new, involve an inventive step, and are capable
of industrial application. Id. at art. 27, 91 1.
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date.36 Article 28 describes the rights conferred on the patentee
and gives patent owners the "exclusive rights ... to prevent
third parties, not having the owner's consent from the acts of:
making, using, offering for sale, selling or importing" products
and processes. 37
The major purpose of the agreement was to induce develop-
ing countries to enact legislation compliant with minimum intel-
lectual property standards. 38 Unfortunately, the implications of
patent protection mean developing countries will experience
significantly higher drug prices.39 The disparate impact that
drug patents will have on developing nations and the pharma-
ceutical industry is enormous. The welfare loss suffered by de-
veloping countries is estimated to be between $3.5 billion and
$10.8 billion, while the gain by foreign patentees is estimated to
fall between $2.1 billion and $14.4 billion.40
2. Treaty-Created Exceptions
TRIPs does provide exceptions for developing countries to
obtain drugs at cheaper prices. Parallel importation, or exhaus-
tion, permits a party to buy a patented drug in one country and
re-sell it in a second country at a lower price than the patentee.
Article 6 of TRIPs states, "For the purposes of dispute settle-
ment under this Agreement, subject to the provisions of Articles
3 and 4 above, nothing in this Agreement shall be used to ad-
dress the issue of the exhaustion of intellectual property
rights. '41 Under international law, once a legal reproduction of
a product has been distributed anywhere in the world, the
rights of that reproduction are exhausted.42
Compulsory licensing also assists countries in increasing
access to cheaper drugs. Compulsory licensing permits a coun-
36. See id. at art. 33.
37. Id. at art. 28, 1(a).
38. See Ruth L. Gana, Prospects for Developing Countries Under the TRIPs
Agreement, 29 VAND. J. TRANSNATL L. 735, 740 (1996). See also John E. Giust,
Noncompliance with TRIPs by Developed and Developing Countries: Is TRIPs Work-
ing?, IND. INT'L. & COMP. L. REV. 69, 70 (1997).
39. See CARLOS M. CORREAS, INTELLECTUAL PROPERTY RIGHTS, THE WTO AND
DEVELOPING COUNTRIES 36 (2000).
40. See id. at 35 (citing Noguds).
41. TRIPs, supra note 35. Articles 3 and 4 address national treatment and
most-favoured nation treatment. See id. at art. 3, 4.
42. See Vincent Chiapetta, The Desirability of Agreeing to Disagree: The WTO,
TRIPs, International IPR Exhaustion and a Few Other Things, 21 MICH. J. INT'L L.
333, 341 (2000).
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try to manufacture a patented drug itself if it pays a royalty to
the patentee. 43 This has the effect of cutting the cost of drugs by
as much as ninety-five percent.44 TRIPs permits the use of com-
pulsory licensing: (1) against any crises in public safety or
health; and (2) to promote public interest in the areas of socio-
economics and development. 45
Article 8 allows Member States to adopt legislative or regu-
latory measures "necessary to protect public health and nutri-
tion, and to promote the public interest in sectors of vital impor-
tance to their socio-economic ... development ... provided that
such measures are consistent with the provisions of this Agree-
ment."46 Article 8 acts as a policy statement for Articles 30, 31,
and 40.47 It suggests that a Member State cannot be prevented
from considering general public policy or public welfare when
enacting post-TRIPs patent laws.48
Article 27 provides exceptions to patents when necessary to
prevent abusive commercial exploitation of the invention and to
protect ordre public, morality, and human life or health.49
There is no generally recognized definition of ordre public,5 0 but
the risk must arise from the invention's commercial exploitation
rather than the invention itself.5' Thus, if a country can prove
its actions are "necessary" to protect public health, it could re-
fuse to grant a patent on a drug and produce and sell the drug
through a non-commercial body.52
Article 31 permits Members to determine the basis for
43. See What is the United States' Role in Combating the Global HIVIAIDS
Epidemic?: Hearing Before the Subcomm. on Criminal Justice, Drug Policy, and
Human Resources, 106th Cong. 152 (1999) (statement of James Love, Director, Con-
sumer Project on Technology).
44. See id.
45. See TRIPs, supra note 35, at art. 8.
46. Id. at art. 8, 1.
47. See GERVAIS, supra note 34, at 68. Article 30 permits parties to provide
limited exceptions to the rights conferred by a patent; Article 31 states the required
conditions for States to implement legislation allowing the use of a patent without
the authorization of the patentee; Article 40 addresses control of anti-competitive
practices in contractual licenses. See TRIPs, supra note 35.
48. See CORREAS, supra note 39, at 7.
49. TRIPs, supra note 35, at art. 27, 2. See also Overview: The TRIPs Agree-
ment, World Trade Organization, at http://www.wto.orgenglishtratop-e/
trips-e/intel2_e.htm#patents (last visited January 13, 2001).
50. See CORREAS, supra note 39, at 62.
51. See GERVAIS, supra note 34, at 148.
52. See Robert Weissman, A Long Strange TRIPs: The Pharmaceutical Industry
Drive to Harmonize Global Intellectual Property Rules, and the Remaining WTO Le-
gal Alternatives Available to Third World Countries, 17 U. PA. J. INT'L ECON. L.
1069, 1109-10 (1996).
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granting compulsory licenses, 53 and limits any compulsory li-
cense issued by restricting it to the purpose for which it was
granted, mandating that the license is non-exclusive, and mak-
ing it non-assignable. 54 A country may grant a compulsory li-
cense if the "user has made efforts to obtain authorization from
the right holder on reasonable commercial terms and conditions
and ... such efforts have not been successful within a reason-
able period of time" and also if the patentee will be adequately
remunerated. 55 Some developing nations believe that compul-
sory licenses should be granted when drugs exist that are capa-
ble of curing or hindering the disease, valuing the right to re-
ceive health treatment above potential economic damages to the
company.56 Public health advocates and many developing na-
tions claim the treaty permits them to produce or import generic
drugs to avert the national disaster of the AIDS epidemic.5 7
Pharmaceutical companies disfavor compulsory licensing and
claim the policy removes any incentive for research and devel-
opment in drugs subject to compulsory licensing.58
Signatory nations to TRIPs must comply with or exceed the
minimum standards set by TRIPs. The agreement gives devel-
oping nations extra time to comply with its provisions. Develop-
ing member nations must comply with TRIPs starting in 2000.59
Least-developed countries are not bound by TRIPs until 2006,60
with possible extensions by the TRIPs Council.61 Despite these
53. TRIPs, supra note 35, at art. 31.
54. TRIPs, supra note 35, at art. 31(c)-(e).
55. Id. at art. 3(b) and (h).
56. See Sara M. Ford, Note, Compulsory Licensing Provisions Under the TRIPs
Agreement: Balancing Pills and Patents, 15 AM. U. INT'L L. REV. 941, 964 (2000).
57. See Donald G. McNeil Jr., As Devastating Epidemics Increase, Nations Take
on Drug Companies, N.Y.TIMES, July 9, 2000, at 8.
58. See Patrick Bond, Globalization, Pharmaceutical Pricing, and South Afri-
can Health Policy: Managing Confrontation with U.S. Firms and Politicians, 29
INT'L J. HEALTH SERVICES 765, 779 (1999) (quoting Harvey Bale, Director-General of
the International Federation of Pharmaceutical Manufacturers in Geneva).
59. TRIPs, supra note 35, at art. 65 (providing developing countries with a
grace period of five years to apply the provisions of the Agreement).
60. Id. at art. 66, 1 (providing these countries with a grace period of 11
years). The justification for providing the least developed country members with a
longer grace period is explained in Article 66: "In view of the special needs and re-
quirements of least-developed country Members, their economic, financial and ad-
ministrative constraints, and their need for flexibility to create a technological base,
such Members shall not be required to apply the provisions of this Agreement.. .for
a period of 10 years..." Id. The delay does not include provisions regarding na-
tional treatment and Most Favored Nation (MFN) status. Id. at art. 66, 1.
61. See id. Article 66, 1 of TRIPs explains that the "needs and requirements
of least-developed country Members, their economic, financial, and administrative
2002]
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extensions, both developing and least-developed nations must
make certain patent services available to patent-seekers. 62
In case of non-compliance, TRIPs provides for World Trade
Organization (WTO) dispute resolution.63 Member States con-
testing the patent laws of another Member may bring a com-
plaint against that State before a Dispute Settlement Panel. If
the State is unhappy with the Panel's decision, it may appeal to
the Appellate Body for review of the panel decision. In addition,
TRIPs requires that Member states provide national processes
and solutions for patentees to enforce their rights effectively.6
3. Drawbacks of the Exceptions
Public health groups believe that impoverished nations are
deterred from utilizing parallel importation or compulsory li-
censing for fear of trade sanctions or legal challenge. 65 Interna-
tional pressure by the pharmaceutical industry on developing
countries to strengthen their intellectual property laws is high.
Such pressure may be brought directly by the pharmaceutical
company against the offending nation in national court systems,
through the WTO dispute resolution system, or by unilateral
threats of trade sanctions.
The United States has been conspicuously active in pressur-
ing other countries to strengthen their patent laws through the
threat of trade sanctions and WTO dispute settlement actions.
The 1988 amendments to the United States Trade Act imple-
mented "Special 301," a statutory provision that allows the
United States to employ trade sanction measures. 66 Special 301,
as a means of putting pressure on countries with weak intellec-
constraints, and their need for flexibility to create a viable technological base." Id.
See also GERVAIS, supra note 34, at 257.
62. TRIPs, supra note 35, at art. 70, 8. This article requires patent services
include a "mailbox" available for pharmaceutical patent applications. This "mail-
box" began accepting filed applications as of January 1, 1995. Id. Also, if a patent
and marketing approval has been granted for a product in one country, the second
country is required to grant an "exclusive marketing right" for that product. Id. at
art. 70, 9. See also U.N. CONF. ON TRADE & DEV., THE TRIPS AGREEMENT AND
DEVELOPING COUNTRIES, at 11, para. 6, U.N. Doc. UNCTAD/ITE/1, U.N. Sales No.
96.II.D.10 (1996).
63. TRIPs, supra note 35, at art. 64, 68.
64. Id. at art. 42-49.
65. See Activists Highlight AIDS Toll During Annual Observance, MED.
INDUSTRY TODAY, Dec. 2, 1999, at 1.
66. See JOHN H. JACKSON ET AL., LEGAL PROBLEMS OF INTERNATIONAL
ECONOMIC RELATIONS 818 (3d ed. 1995).
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tual property protection laws, permits the United States Trade
Representative (USTR) to begin investigations upon citizen peti-
tion or its own initiative.67 Under the Generalized System of
Preferences (GSP), the United States may threaten trade sanc-
tions against any trading country that does not provide "ade-
quate and effective protection of intellectual property rights" or
denies "fair and equitable market access to U.S. persons who
rely upon intellectual property protection."68 Furthermore, the
USTR may list suspect countries as "Priority Foreign Coun-
tries," "Priority Watch List Countries," or "Watch List Coun-
tries."69 This listing may lead to negotiations or trade sanctions
if the country fails to change its patent laws to satisfy the
United States.70
Thailand is one example of a country where the United
States successfully tightened patent laws by threatening trade
sanctions. In 1992, Thailand amended its Patent Act of 1979 to
allow compulsory licensing and parallel importing. 71 This legis-
lation directly conflicted with United States interests when
Thailand began producing a generic version of the HIV antiret-
roviral didanosine (ddI).72 After threats of trade sanctions,
Thailand halted its generic ddI production. 73 Responding to
pressure from the United States, Thailand again amended the
Patent Act in 1999, effectively eradicating parallel importing
and restricting compulsory licensing.74
If the AIDS crisis in Thailand is a "national emergency," ar-
67. See id.
68. 19 U.S.C. §§ 2461-67 (1998).
69. See Judith H. Bello & Alan F. Holmer, "Special 301" Its Requirements, Im-
plementation, and Significance, 13 FORDHAM INT'L L.J. 259, 266-67 (1990) (Titles are
in order of decreasing perceived violations).
70. See id. at 262-63.
71. See Rosemary Sweeney, The U.S. Push for Worldwide Patent Protection for
Drugs Meets the AIDS Crisis in Thailand: a Devastating Collision, 9 PAC. RIM. L. &
POL'Y 445, 451 (2000).
72. See Bond, supra note 58, at 775.
73. See id.
74. See Sweeney, supra note 71, at 449 (citing Thailand Patent Act (No. 3) B.E.
2542 (1999) Art. 36(7)). The 1999 Amendments explicitly prohibit parallel importing
without the patentee's permission. See id. As a result, it is illegal to import generic
drugs into Thailand, even from countries where drugs are unprotected by patents
and generic production is legal. See id. By specifically addressing parallel importa-
tion, Thailand's 1999 Act gives more protection against parallel importation than
TRIPs. Compare TRIPs, supra note 35, at art. 6 with Thailand Patent Act (No. 3)
B.E. 2542 (1999) Art. 36(7) (cited in Sweeney, supra note 71, at 449). The Amend-
ments also limit the Thai government's ability to grant compulsory licenses. See
Sweeney, supra note 71, at 452.
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guably Thailand should be able to grant compulsory licenses le-
gally under TRIPs and its 1999 Act. The threat of United States
sanctions has made pursuing this route undesirable. 5 The
United States is Thailand's biggest export market, totaling
$12.65 billion in 1999.76 Moreover, because the United States
market promises great economic benefit, Thailand will be reluc-
tant to risk losing the United States as a commercial partner.77
Currently, Thailand is on the United States "Regular Watch
List."78 Between the benefits of compulsory licensing and the
possibility of trade sanctions, it is likely that Thailand will avoid
sanctions and renounce compulsory licensing.
C. SOUTH AFRICA
South Africa's current patent laws are codified in the Medi-
cines and Related Substances Amendment Act. South Africa
amended its Medicines and Related Substances Act 101 in 1997
to give its Minister of Health discretion over when to grant com-
pulsory licenses for the production of generic medicines. 79 Spe-
cifically, the amendment grants the Minister of Health the
power to allow for compulsory licensing, provided the drug was
initially marketed by the patentee or with the patentee's con-
sent and the drug does not have other expressed restrictions.80
Some feel that Article 15(C)(a) of the South African Act ends
patent rights by stating that pharmaceutical patent rights
"shall not extend to acts in respect of such medicine which has
been put onto the market."8' Interpreted broadly, this provision
could deny patentee protection once they begin to sell their
75. See Sweeney, supra note 71, at 463-64.
76. Thailand's Exports Increase Seven Percent in 1999, XINHUA, Feb. 28, 2000,
at 2000 WL 14191093. Thailand's total exports in 1999 amounted to $58.49 billion.
Id.
77. For example, Thai exports to the United States increased 17.7% in the first
seven months of 2000. See Commerce Ministry Says Climate Right for Further Ex-
port Growth, Bus. DAY (THAIL.), Sept. 5, 2000, at 2000 WL 6317728.
78. See Sweeney, supra note 71, at 462. From 1989, the USTR moved Thailand
through a series of watch lists, from "priority watch list" (1989), to "priority foreign
country" (1991) to "priority watch list" (1993) to "regular watch list" (1994) in re-
sponse to moves by Thailand to strengthen intellectual property laws. See id. at
460-62 (citations omitted).
79. See Duane Nash, South Africa's Medicines and Related Substances Control
Amendment Act of 1997, 15 BERKELEY TECH. L. J. 485, 492 (2000).
80. Medicines and Related Substances Control Amendment Act, No. 90, § 10
(1997) (S. Afr.) [hereinafter Medicines] (referring back to Medicines and Related
Substances Control Amendment Act, No. 101, § 15(C) (1965)).
81. Id.
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drugs.82 The Act also weakens patent protection under 15(C) by
permitting parallel importation under 15(C)(b). 83
The international response to Article 15(C) was swift.
United States government officials proposed bilateral trade
sanctions to pressure South Africa to repeal the amendment.
The USTR placed South Africa on the "Watch List," and the
White House tentatively withheld preferential tariff treatment
for four South African exports.84 The Pharmaceutical Manufac-
turers' Association (PMA) of South Africa, on behalf of forty do-
mestic and international pharmaceutical companies, brought a
lawsuit against the South African government upon the enact-
ment of the Act.8 5 After the suit was filed, the South African
government passed the South African Medicines and Medical
Devices Regulated Authority Act (SAMMDRA), which rescinded
the Medicines and Related Substances Amendment Act and the
amendment. Due to various failings of SAMMDRA, President
Mandela repealed it. In response, the courts ruled that Presi-
dent Mandela acted outside of his executive power when he re-
scinded SAMMDRA.86 The PMA put its lawsuit on hold while
the Minister of Health agreed to consider legislation that would
better comply with TRIPs.8 7 In April 2001, the PMA made a
startling move announcing that it would drop the lawsuit en-
tirely.88 Since then, no other drug industry has challenged
82. See id.
83. See id. See also David Benjamin Snyder, South Africa's Medicines and Re-
lated Substances Control Act: A Spoonful of Sugar or a Bitter Pill to Swallow? 18
DICK. J. INT'L L. 175, 186 (1999).
84. See Bond, supra note 58, at 771, 774. The State Department reported that
it would "...continue our unflagging efforts to convince the South African Govern-
ment to either repeal Article 15(C) or make it consistent with the TRIPs agreement,
and thus eliminate the possibility that any abrogation of U.S. pharmaceutical patent
rights in South Africa. Should there be an actual violation of any U.S. pharmaceuti-
cal patent right (e.g. patent abrogation) this Administration will respond forcefully
in accordance with appropriate trade remedy legislation." Id. at 774 (citations omit-
ted).
85. See Lynn Woods, Government AIDS Efforts To Target Drug Makers: Phar-
maceuticals Act to Stop Backlash Against their IP Rights, Bus. WITHOuT BORDERS,
Aug. 2000, at 18, in CORP. LEGAL TIMES (Aug. 2000). The lawsuit was later put on
hold. See also McNeil, supra note 57 (describing when South Africa attempted to
pass legislation permitting the health minister to disregard TRIPs in health crises,
the U.S. pressured South Africa with threats of trade sanctions).
86. See Woods, supra note 85.
87. See Drug Patents: Clash Averted for Now, FIN. MAIL (S. Aft.), Sept. 24,
1999, at 14, available at 1999 WL 16764741. See also Gumisai Mutume, Trade: U.S.
Drug Companies Ease Up on South Africa, INTER PRESS SERVICE, Sept. 12, 1999,
available at 1999 WL 27373954.
88. See Campaign Accomplishments for 2001, CAMPAIGN FOR ACCESS To
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South Africa's laws within the South African court system.
In response to growing international pressure by AIDS ac-
tivists and public health groups8 9 over the growing problem of
access to drugs, President Clinton issued an executive order to
promote access to HIV/AIDS medicines on May 10, 2000.90 The
order permits sub-Saharan Africa to regulate privately patented
pharmaceuticals, 91 provided the legislation still complies with
TRIPs. The order also permits United States government offi-
cials to evaluate and take action if a law or policy is inconsistent
with the TRIPs agreement. 92 The order protects South Africa
from United States trade retaliation or WTO dispute settlement
in regard to its patent laws.
Following President Clinton's executive order, the five larg-
est pharmaceutical companies promptly signed an agreement
with the United Nations to cut the price of HIV/AIDS drugs up
to eighty percent for impoverished countries.93 Bristol-Myers
Squibb, Roche, Boehringer Ingelheim, Glaxo-Wellcome, and
Merck & Company offered lower prices for various HIV/AIDS
drugs.94 The impact of this gesture is diminished by the exis-
tence of cheaper generics in Thailand, India, and Brazil.95 The
eighty percent reduction is inadequate to make the drugs af-
fordable to most Africans.
Fortunately, the HIV/AIDS problem is a crisis recognized by
the world. Nations, nongovernmental organizations (NGOs),
and intergovernmental organizations (IGOs) have donated mil-
EFFECTIVE MEDICINES (Mddecins Sans Frontiores, Brussels, Belgium), Apr. 23,
2001.
89. See generally Activists Highlight AIDS Toll During Annual Observance, su-
pra note 65.
90. Exec. Order No. 13155, 3 C.F.R. 268-70 (2000). "This order prohibits the
United States Government from taking action pursuant to section 301(b) of the
Trade Act of 1974 with respect to any law or policy in beneficiary sub-Saharan Afri-
can countries that promotes access to HIV/AIDS pharmaceuticals or medical tech-
nologies and that provides adequate and effective intellectual property protection
consistent with the TRIPS Agreement." Id.
91. See id. See also Neeraj Kaushal, EcoScope: Not by Aid Alone, ECON. TIMES,
May 16, 2000, at 2000 WL 16892773.
92. See Exec. Order 13155, supra note 90.
93. See Kaushal, supra note 91.
94. See Companies Agree to Cut Prices of HIV Drugs in Poor Nations, MED.
INDUSTRY TODAY, May 12, 2000, at 1. Glaxo-Wellcome (UK) will offer Combivir
(AZT and 3TC) at a cost of $2, compared with $16.50 in the United States. See id.
Bristol-Myers Squibb (US) intends to increase access to antiretroviral drugs, Videx,
Zerit, Megace, and Fungizone. See id. Roche (Switzerland) will offer developing
countries better rates. See id.
95. See Kaushal, supra note 91.
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lions of dollars in drugs, services, and assistance to combat this
disease. Yet, these efforts still fall short of supplying the major-
ity of the thirty-six million people with the medication they des-
perately need. One promising alternative for South Africa is to
seek affordable drugs through the generic drug sector.
D. GENERIC DRUGS
The generic drug industry is a viable solution for increasing
the affordability of essential medicines. By producing copied
versions, generic companies are able to provide cheaper versions
of otherwise unaffordable drugs. The average price of
HIV/AIDS drugs in South Africa was eighty-two percent less
than prices in the United States because of the availability of
generic drugs.96 The international organization Doctors Without
Borders found that in most cases, even if brand-name prices
were reduced eighty-five percent, the prices would still not drop
as low as generic copies. 97
Brazil provides one example of how access to generic drugs
can revolutionize the fight against AIDS. In 1971, Brazil took
steps to make medicines available to impoverished Brazilians
and created Central de Medicamentos (CEME). 98 CEME pro-
posed assisting state-owned laboratories and giving preferential
treatment to domestic companies. In short, CEME promoted
the domestic production of most AIDS drugs.99 From 1969 to
1994, there was no Brazilian patent protection available for in-
ternational pharmaceutical products or procedures. 100 Instead,
Brazil's pharmaceutical companies produced generic drugs with
astounding success. 10 1 In fact, Brazil's pharmaceutical market
is now the fourth largest in the world, grossing over $8 billion. 0 2
By producing generic drugs, Brazil forced prices of imported
drugs down through domestic competition and lowered its
AIDS-related death rate. 03 In 1996, Brazil used compulsory li-
96. See P~rez-Casas, supra note 2, at 9.
97. See id.
98. See Mayer, supra note 32, at 379. Despite the lack of protection for drugs,
foreign investment in Brazil's pharmaceutical industry increased from $113 million
in 1971 to $646 million in 1979. See id. at 380 (citations omitted).
99. See id. at 379 (citations omitted).
100. See Gary Gereffi, THE PHARMACEUTICAL INDUSTRY AND DEPENDENCY IN
THE THIRD WORLD 229 (1983).
101. See Mayer, supra note 32, at 380; see also GEREFFI, supra note 100.
102. See e.g., New Intellectual Property Law in Brazil, 8 J. PROPRIETARY RTS. 34
(1996).
103. See AIDS in Africa, supra note 19.
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censing to make antiretrovirals available to all persons infected
with HIV/AIDS. 104 Brazil's public health system can administer
antiretroviral therapy to 1000 people living with HIV/AIDS for
the same cost that the Ugandan government spends to treat two
hundred twenty-eight people living with HIV/AIDS. 10 5 As a re-
sult, AIDS mortality in Brazil plummeted by half of its projected
rate by the end of 1999.106
Yet, even the generic drug sector is not immune to legal
challenge and skirmishes. India, a major producer of generic
drugs, is one example of the legal battle that confronts the ge-
neric industry. Indian companies are among the largest generic
drug manufacturers and control eighty-five percent of the In-
dian pharmaceutical market. 10 7 The Indian generic drug indus-
try earns $900 million annually from domestic sales alone.108
This extensive market control by the generic sector is due to In-
dia's weak patent laws, which did not provide patents for phar-
maceutical products. 10 9 As a result, Indian-owned companies
could copy an existing drug without paying a patent fee. 110 Fur-
thermore, Indian generic companies reduced their need to invest
in research and development by simply copying the drugs, which
enabled them to keep their drug prices low."'
The United States placed India on its "Priority Watch List"
in 1996 for its lack of protection for patented pharmaceutical
drugs. 1 2 It claimed its pharmaceutical industry lost $450 mil-
lion due to India's weak patent protection laws."13 India and the
104. See Claire Bisseker, The Thrning of the Tide, FIN. MAIL, July 21, 2000, at
2000 WL 8448820.
105. See Pdrez-Casas, supra note 2, at 12. Antiretroviral therapy of ddI 400mg
+ d4T 80 mg daily costs $78 per month in Brazil, where it is manufactured locally as
generics. See id. In Uganda, the cost is $342 per month, as there are no generics
available. See id.
106. See Bisseker, supra note 104.
107. See David K. Tomar, A Look Into the WTO Pharmaceutical Patent Dispute
Between the United States and India, 17 WIS. INT'L. L. J. 579, 592 (1999). See also
India's Lax Patent Regime Hits U.S. Pharmaceutical Companies, MARKETLEErER,
Jan. 19, 1998, available at 1998 WL 9220214.
108. See George K Foster, Opposing Forces in a Revolution in International Pat-
ent Protection: The U.S. and India in the Uruguay Round and Its Aftermath, 3
UCLA J. INT'L L. & FOR. AFF. 283, 307 (1998).
109. See Tomar, supra note 107, at 583-84.
110. See id. at 584.
111. See J.H. Reichman, Compliance with the TRIPs Agreement: Introduction to
a Scholarly Debate, 29 VAND. J. TRANSNAT'L L. 363, 379 (1996).
112. See U.S. Opens Investigation into Protection of Intellectual Property Rights
in India, 13 INT'L TRADE REP. (BNA) 1117, July 10, 1996.
113. According to the USTR, India neither provided a permanent mailbox sys-
tem nor did it have a system to grant exclusive marketing rights to inventors. See
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United States were unable to resolve their differences, so they
presented the issue to the WTO Dispute Settlement Panel.114
The United States prevailed on its claim, and India appealed. 15
The WTO Appellate Body held that India had not complied with
TRIPs and ordered India to do so. 16 Meanwhile, the United
States continues to battle the generic industry, and it recently
began proceedings in the WTO dispute settlement system to de-
termine possible violations of TRIPs by Brazil. The United
States claims that Article 68 of Brazil's 1996 Industrial Property
Law discriminates against U.S. patented products that are im-
ported into, but not produced within, Brazil. 117
Based on the experiences of Thailand, Brazil, and India, it
would appear likely that South Africa faces similar threats of
trade sanctions or dispute settlement in the WTO. Yet, as the
analysis will argue, such a fate for South Africa is improbable
due to international law, public relations, and increasing global
HIV/AIDS awareness.
II. ATTEMPTS TO INCREASE DRUG AVAILABILITY IN
SOUTH AFRICA
A. TRIPS
"We need life-saving action, not litigation, not lawsuits.""8
The words of Representative Barbara Lee reflect the growing
sentiment by the international community, the NGO sector,
governments, and even the pharmaceutical industry that the
battle against AIDS cannot be hampered by legal fights. Yet, in
spite of these valiant words, pharmaceutical companies and de-
veloped nations often use TRIPs to challenge patent laws in de-
USTR to Investigate India's Protection of Intellectual Property Rights, 8 J.
PROPRIETARY RIGHTS 10, Oct. 1996.
114. See U.S. -India Patent Dispute Continues, 9 J. PROPRIETARY RIGHTS 6, at 33,
June 1997.
115. See Report of the Panel, India-Patent Protection for Pharmaceutical and
Agricultural Chemical Products, at 63, WTO Doc. WT/DS50/6 (1997). The WTO
Dispute Panel originally found that India failed to comply with art. 70(8)(a) of
TRIPs, or, in the alternative, article 63(1) and (2). Id.
116. See Report of the Appellate Body, India-Patent Protection for Pharmaceuti-
cal and Agricultural Chemical Products, at 33-34, WTO Doc. WT/DS50/AB/R (1997).
117. See Sarah Boseley, Opinion: Pharmaceuticals Move Their Battleground to
Brazil to Stem the Tide of Cheaper Drugs-Drug Companies are now Focusing on
South America to Prevent Cheap Generic AIDS Drugs from Reaching the United
States, IRISH TIMES, Apr. 20, 2001, at 14.
118. See 147 CONG. REC. H995, supra note 10 (statement of Rep. Lee).
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veloping countries. The international community has already
encountered litigation over TRIPs between the United States
and India. After a prolonged dispute, India was ordered to
strengthen its patent laws to conform to TRIPs. 119 Currently,
the world is witnessing a "re-play" of the United States-India
dispute, as the United States takes Brazil before the WTO
panel, challenging its patent laws under Articles 27.1 and 28.1
of TRIPs. 120 This leads to the question of how international law
affects South Africa's access to medicines and whether South
Africa's laws can stand up to legal challenge.
South Africa's circumstances resemble those of India and
Brazil, making it appear prone to the same legal challenges.
Like India and Brazil, South Africa has a high number of people
living with HIV/AIDS. In fact, South Africa has the highest in
the world.' 2' Like these countries, South Africa is a developing
country seeking to improve its access to affordable drugs
through legislation. 122 Unlike India and Brazil, South Africa
has successfully evaded legal challenge and retaliation over its
patent legislation.
One possible legal conclusion that explains why South Af-
rica has not been haled before the WTO panel is because Article
15 simply does not violate any provision of TRIPs. Representa-
tive Lee remarked, "everyone from international patent experts
to the World Health Organizations agrees that the South Afri-
can Medicine Act is perfectly legally sound." 23 This appears to
be somewhat of an overstatement; forty drug companies dis-
agreed. 124 Specifically, the pharmaceutical industry found fault
with South Africa's provisions on parallel importation and com-
pulsory licensing.' 25
1. Parallel Importation
South Africa permits parallel importation under Article
119. See Report of the Appellate Body, supra note 116, at 64.
120. See South Africa's Moral Victory, LANCET, Apr. 28, 2001, at 2001 WL
10158573.
121. See Report, supra note 3.
122. See Bess-Carolina Dolmo, Examining Global Access to Essential Pharma-
ceuticals in the Face of Patent Protection Rights: The South African Example, 7
BUFF. HUM. RTs. L. REV. 137, 140-41 (2001).
123. See 147 CONG. REC. H995, supra note 10 (statement of Rep. Lee).
124. See Woods, supra note 85.
125. See Marina Jimenez, Companies Fight Law Allowing Cheap, Generic AIDS
Drugs: Test Case in South Africa, NATL. POST, (Mar. 6, 2001), available at 2001 WL
14438143.
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15(C)(b) of its Medicines and Related Substances Control
Amendment Act. Article 15(C)(b) states that a drug that "meets
the same quality standards and is intended to have the same
proprietary name as that of another medicine already registered
in the Republic, but which is imported by a person other than
the person who is the holder of the registration certificate ...
may be imported." 126 It is debatable whether TRIPs prohibits
parallel importation. Barfield and Groombridge argue that the
parties to TRIPs "agreed to disagree" over the parallel importa-
tion issue. 127 They set forth several arguments for parallel
trade, including reduced impetus for research and development
and serious health and safety concerns over counterfeit drugs.
However, Article 6 clearly states, "nothing in this Agreement
shall be used to address the issue of the exhaustion of intellec-
tual property rights."128 Many scholars feel that because TRIPs
fails to address parallel importation, it does not prohibit it.129
Thus, a WTO Member should be free to import the cheapest
drug available from another nation where the drug is legally
sold to re-sell within its own territory. Presumably, an opposing
Member State cannot argue international exhaustion as a viola-
tion of TRIPs.' 30 Another common argument against a prohibi-
tion construction is that construing TRIPs to restrict parallel
imports would conflict with the fundamental principles of free
trade upon which the WTO rests.1 3' Arguably, parallel importa-
tion is a domestic legal issue about which the South African
government is free to decide.132
Recognizing the questionable quality of drugs produced in
other developing countries and Kenya's recent experience in
parallel importation, South Africa may be deterred from using
parallel importation to get less expensive medicines. Develop-
ing countries often lack the technological capability to develop
and dispense generic drugs safely.' 33 In Kenya's experience
126. See Medicines, supra note 80.
127. See Claude E. Barfield & Mark A. Groombridge, Parallel Trade in the
Pharmaceutical Industry: Implications for Innovation, Consumer Welfare, and
Health Policy, 10 FORDHAM I.P., MEDIA & ENT. L.J. 185, 191 (1999).
128. See id.
129. See e.g., Nash, supra note 79, at 490 (citations omitted); see also Snyder,
supra note 83, at 188.
130. See Snyder, supra note 83, at 188.
131. See Barfield, supra note 127, at 191.
132. See Nash, supra note 79, at 494.
133. See Bisseker, supra note 104. This ineptitude can result in drug resistance
or inactive ingredients. See also Compulsory Licensing: Activists Demonstrate at
WTO, AM. HEALTH LINE, Nov. 1999.
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with parallel importation, it found "alarming evidence" of sub-
standard and counterfeit drugs, faced difficulties in recalling
unsafe products, and dealt with consumer confusion over multi-
ple brands of the same drug.134 Ultimately, Kenya proscribed
the parallel importation of drugs due to safety concerns. 135
Despite such problems, South Africa has chosen to import
generic drugs from India for HIV/AIDS treatment. Cipla, an
Indian generic drug manufacturer, recently offered to sell its
triple-combination therapy for $350 per year per patient and to
governments for $600 per year.136 The $350 price is ninety-six
percent lower than the United States price. 137 Shortly following
this announcement, a second Indian generic drug producer of-
fered to sell the triple-combination therapy for $347 per year per
patient to a South African generic drug firm. 138 In sum, parallel
importation offers a legal and economically attractive option
that South Africa is willing to accept.
2. Compulsory Licensing
Although the circumstances are limited, TRIPs leaves loop-
holes in the patent drug market for the generic manufacture of
HIV/AIDS medicines. Under Articles 27 and 31, TRIPs permits
compulsory licensing, subject to conditions that limit the domes-
tic manufacturer's production of generic copies to certain cir-
cumstances. The relevant provisions require that compulsory li-
censing can be necessary to protect human life and health or to
address a national emergency. 139 Some trade experts argue that
Article 27.1 allows patents to be enjoyed without discrimination
and therefore, any program for compulsory licensing based on
public health is discriminatory. 140 However, most trade experts
view this interpretation as absurd and cite the broad scope of
TRIPs to permit compulsory licensing on nearly all public health
134. See Claire Bisseker, Beware of Counterfeit Medicines, Kenya Warns South
Africa Medicines Control, 40 FIN. MAIL, Oct. 24, 1997, at 40.
135. See id.
136. See Press Release, M~decins Sans Frontinres Campaign for Access to Es-
sential Medicines, AIDS Triple-Therapy for Less Than $1/Day, Feb. 7, 2001, at
http://www.accessmed-msf.org/ (last visited Oct. 14, 2001).
137. See id.
138. See Inside the Industry Merck: Lowers AIDS Drugs Prices for Africa, 6 AM.
HEALTH LINE 9, 2 (Mar. 8, 2001). Hetero Drugs, Ltd. entered into an agreement
with Aspen Pharmacare, Ltd., a South African generic drug firm, to distribute ge-
neric drugs. See id.
139. See TRIPs, supra note 35, at art. 27, 31.
140. See Bond, supra note 58, at 777 (citations omitted).
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grounds. 141
Under Article 27, the issue of whether compulsory licensing
is necessary to protect human life or health in South Africa has
two counter-arguments. 142 First, the standard is "necessary,"
suggesting that no alternatives exist. 143 While supplying an-
tiretrovirals is an important follow-up treatment for post-HIV
diagnosis, pharmaceutical companies, the health care sector,
and activists recognize that education, prevention, diagnosis,
and counseling are also vital measures to preserve human life
and health amidst the AIDS crisis. In fact, South Africa has fol-
low-up support and established care procedures for HIV-positive
patients.'" Moreover, it provides programs that educate and
prevent the spread of HIV, including HIV-specific testing.
Alongside the array of preventative programs available, drug
treatment is not the only means of protecting life and health of
South Africans during the AIDS crisis. As the Special Session of
the United Nations General Assembly noted, antiretroviral
therapy is not a cure for people dying of AIDS;145 it merely re-
duces the presence of the virus.
The terminal progress of AIDS and staggering number of
AIDS-related deaths is highly persuasive evidence that compul-
sory licensing is necessary to protect human life or health. A
death from AIDS is a premature death. Most people who ac-
quired HIV from unprotected sex are in their twenties or thir-
ties.146 A majority of these people can expect to die within ten
years. 147 If these people had triple combination therapy, the
mortality rates would be dramatically lowered. Despite the exis-
tence of effective therapy, several thousand South Africans con-
tinue to die each day from AIDS because of the unaffordable
price of drugs. 48
Moreover, the number of children left orphaned as a result
of AIDS is overwhelming. Already, AIDS has orphaned 13.2
million children, and twenty to twenty-five percent of homes in
141. See id.; see also TRIPs, supra note 35, at art. 31.
142. See TRIPs, supra note 35.
143. See Gervais, supra note 34, at 150.
144. See Epidemiological Fact Sheet-South Africa-2000 Update: On HIVIAIDS
and Sexually Transmitted Infections, UNAIDS, at 8, available at
http://www.unaids.org/hivaidsinfo/statistics/juneOO/fact-sheets/pdfs/southafrica.pdf
(last visited Sept. 15, 2001).
145. See Special Session, supra note 1, 98.
146. See id.
147. See id. Ten years is the average number of years for these people to live.
See id.
148. See 147 CONG. REC. H995, supra note 10 (statement of Rep. Lee).
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Africa have orphans. 149 These children face a difficult life, not
only because of the loss of their parents, but also because chil-
dren orphaned by AIDS face a higher risk of malnutrition, ill-
ness, abuse, and sexual exploitation than other orphans. 10
UNAIDS projects that by 2010, approximately forty million Af-
rican children will be orphans due to AIDS. 151 In light of these
factors, it follows that education, prevention, testing, and follow-
up care do not constitute alternative measures for those who al-
ready have AIDS or are orphaned as a result of AIDS. In fact,
increasing access to essential drugs seems vital to reducing the
effects of this disease, elongating lives, and protecting the
health and well-being of children. By increasing the afforda-
bility of drugs, the availability could stem mortality and reduce
the numbers of children orphaned by AIDS-related deaths.
The impact of AIDS on the development, social, and eco-
nomic infrastructure is another reason justifying South Africa's
legislation. Article 8 permits legislation that is necessary to
protect public health and to promote public sectors of impor-
tance to South Africa's socio-economic development. 52 South
Africa's situation certainly meets the level of a socio-economic
disaster in terms of development and education. The UN Pro-
gramme Coordinating Board has declared the HIV/AIDS situa-
tion in sub-Saharan Africa a development crisis. 53 AIDS is "re-
versing decades of development" in the worst hit areas. 5 4 In
fact, if the AIDS pandemic continues at its present rate, these
areas can expect to lose approximately twenty-five percent of
their economic growth over the next twenty years. 155 Also, its
destructive impact on education is startling. AIDS diminishes
the availability of qualified teachers, financial resources and the
quality of education. It also forces numerous children to drop
out of school to assist at home. 56 A review of the problem of
HIV/AIDS by the UN Secretary General succinctly describes the
socio-economic development crisis created by AIDS:
149. See Special Session, supra note 1, 31.
150. See id.
151. Framework for the International Partnership Against AIDS in Africa,
UNAIDS Programme Coordinating Board, Provisional Agenda Item 7,
UNAIDS/PCB(9)/00.4, (May 2000), available at http://www.unaids.org/aboutl
governance/files/pcb9-00.4-e.doc [hereinafter Framework].
152. See TRIPs, supra note 35, at art. 8
153. See Framework, supra note 151, at 1.
154. Special Session, supra note 1, 23.
155. See id. 1 1.
156. See id. 29.
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It changes family composition and the way
communities operate, affecting food security
and destabilizing traditional support systems.
By eroding the knowledge base of society and
weakening production sectors, it destroys so-
cial capital. By inhibiting public and private
sector development and cutting across all sec-
tors of society, it weakens national institu-
tions. By eventually impairing economic
growth, the epidemic has an impact on in-
vestment, trade and national security, leading
to still more widespread and extreme poverty.
In short, AIDS has become a major challenge
for human security.157
The HIV/AIDS epidemic constitutes an Article 31 "national
emergency" for South Africa. Furthermore, recognition by the
international community of the magnitude of South Africa's
situation is intensifying. In an effort to combat the spread of
HIV and decrease its impact on human suffering, UNAIDS has
created an International Partnership against AIDS in Africa. 58
If the H1V/AIDS situation in South Africa does not constitute a
national emergency for purposes of compulsory licensing, then it
is difficult to imagine what mass epidemic would.
B. PUBLIC RELATIONS
In addition to the legal arguments for the validity of South
Africa's laws under TRIPs, there are compelling political factors
that safeguard South Africa from challenge. It is doubtful that
any country or drug company will challenge South Africa in any
legal forum over its drug laws and policies due to other factors,
including public relations and government policies.
Public relations is a factor that promises to shield South Af-
rica from legal challenges and expand its pool of drug sources.
The drug industry depends on public relations to increase con-
sumption of its products. 15 9 Yet disapproval of developed coun-
tries' policies regarding access to drugs, especially toward the
157. Id. 23.
158. See id. 56.
159. See Bond, supra note 58, at 782.
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United States and other governments, is highly visible.160 Con-
demnation of restrictive United States policies is evident from
frequent public demonstrations that express concern about the
United States impeding developing countries from gaining ac-
cess to essential drugs.16'
The recent withdrawal of the lawsuit against South Africa
by 40 pharmaceutical companies demonstrates the potential of
public relations to change South Africa's future in medicines.' 62
Although no country has taken South Africa before a WTO dis-
pute resolution panel, the pharmaceutical industry attempted to
challenge South Africa in its national court system. The phar-
maceutical companies questioned three portions of South Af-
rica's laws: the legality of parallel importation, the applicability
of the compulsory licensing, and the discretion granted to the
Minister of Health when deciding to grant compulsory li-
censes. 163 The pharmaceutical companies chose to drop the law-
suit, citing the need to cooperate and collaborate, not litigate. 164
Despite this explanation, it was becoming increasingly clear
that the HIV/AIDS epidemic in South Africa probably qualified
under the compulsory licensing exception because of the public
health crisis. More importantly, the lawsuit was rapidly turn-
ing into a public relations disaster. 65 People worldwide opposed
the lawsuit. For example, 300,000 individuals and 140 groups
across 130 nations signed a worldwide petition to pressure the
PMA to withdraw its suit.166 Had the pharmaceutical industry
pursued litigation, it may have been required to reveal sensitive
information about its research and development costs, profit
margins, and marketing costs. This information would likely
have caused public disapproval. 67 The withdrawal probably
benefits other developing nations seeking cheaper drugs. In
160. See generally Woods, supra note 85; See also Dzulkifli Abdul Razak, Let's
Give Hope to AIDS Victims, N. STRAITS TIMEs, July 16, 2000, at 27, available at
2000 WL 22840920.
161. See Activists Highlight AIDS Toll During Annual Observance, supra note
65.
162. See Campaign Accomplishments for 2001, supra note 88.
163. The pharmaceutical companies challenged the constitutionality of the dis-
cretion granted to the Minister of Health under South Africa's constitution. See
Adele Baleta, Drug Firms Take South Africa's Government to Court, THE LANCET,
(Mar. 10, 2001), available at 2001 WL 10158293.
164. See South Africa Settles Patent Dispute with Drug Industry, ANDREWS
PHARM. LITIG. REP., May 2001, at 13.
165. See South Africa's Moral Victory, supra note 120.
166. See Campaign Accomplishments for 2001, supra note 88.
167. See South Africa's Moral Victory, supra note 120.
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light of the ill-fated lawsuit and disastrous public relations ef-
fect, Ellen 't Hoen of Doctors Without Borders remarked that it
was unlikely the drug companies would challenge another de-
veloping country in court in the near future. 68
In addition to shielding South Africa from legal challenges,
public relations also expand the pool of affordable drugs avail-
able to South Africa. For example, many pharmaceutical com-
panies are touting their humanitarian efforts to increase access
to HTV/AIDS drugs. In general, altruistic efforts have not been
the foremost consideration of the pharmaceutical industry. As
one spokesman for a pharmaceutical company stated, "The in-
dustry has never been philanthropic. It has always made prod-
ucts with an aim of getting a return on investment." 69 Yet, as
the HIV/AIDS crisis grows, so do the humanitarian efforts by
pharmaceutical companies. The recent offer of discounted
HIV/AIDS drugs by the five largest pharmaceutical companies
demonstrates this growing realization that they must improve
their public image. 70
The effect discounted prices will have on increasing access
to drugs is questionable. Many sub-Saharan citizens would not
be able to afford the drugs even if they were available at an
eighty percent discount.' 7' Triple drug therapy would still cost
$2,000 per year, and considering the per capita income in Africa
is less than fifty dollars per month, 72 that is a price beyond the
reach of most South Africans. 7 3 The pharmaceutical companies
have recognized this conundrum and announced further reduc-
tions this year. Last March, Merck & Company declared it
would lower prices of its two AIDS drugs for certain developing
nations. 74 One week following this announcement, Bristol-
168. See Press Release, Mddecins Sans Frontidres Campaign for Access to Es-
sential Medicines, Drug Companies in South Africa Capitulate Under Barrage of
Public Pressure, (Apr. 19, 2001), available at http://www.accessmed-msf.org
prod/publications.asp?scntid=218200141159&contenttype=PARA& (last visited Oct.
14, 2001).
169. See Razak, supra note 160.
170. See Companies Agree to Cut Prices of HIVIAIDS Drugs in Poor Nations,
supra note 94.
171. See AIDS in Africa, supra note 19. "Even with price reductions of up to
80%, most Sub-Saharan nations will not be able to provide long-term drug treatment
for 20-30% of their citizens." Id.
172. See Woods, supra note 85.
173. See Joel Lexchin, Patents on AIDS Drugs Are Patently Unnecessary, GLOBE
& MAIL, Sept. 4, 2000, at A13.
174. See Karen DeYoung & Bill Brubaker, Another Firm Cuts HIV Drug Price:
Sub-Saharan Africa Is the Focus of Bristol-Myers Move, WASH. POST, March 15,
2001, at Al.
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Myers Squibb Company declared it would sell two AIDS drugs
at "below cost" to sub-Saharan African countries. 175 Despite
these reductions, prices for these drugs will not fall as low as
generic prices. 176 Although Videx will now sell for $0.85 in
South Africa, the same drug is still available in Thailand for
$0.36.177
Other companies have taken price reduction a step further
by donating the drugs. The German company Boehringer-
Ingelheim offered Viramune, its version of Nevirapine, free for
five years. 178 Recently, South Africa accepted a fifty million dol-
lar donation of fluconazole from Pfizer. 179 Yet, even donations
by pharmaceutical companies are viewed critically by drug con-
sumers as ineffective and transparent public relations efforts.
After Bristol-Myers Squibb donated drugs totaling one hundred
million dollars, some observers viewed the donation critically,
stating that the donation amounted to only three to four dollars
per HIV-positive African. 80 By itself, the humanitarian factor is
not enough to pave the way to vital medicines for all of South
Africa's needy, but these gestures do expand South Africa's ac-
cess to drugs.
C. POLITICAL INFLUENCE
A second factor that influences South Africa's access to
drugs is political influence. Awareness in the international com-
munity and the United States is escalating due to coverage by
the media and the responsive agendas of NGOs and IGOs.
General public sentiment favoring increased access to medicines
175. See id. Bristol-Myers will charge $1 per day per patient for its drugs Zerit
and Videx. See id.
176. See id. Merck will charge $600 per year per patient for Crixivan, a protease
inhibitor. See id.
177. See id.
178. See Andrew Stawicki, Africa Waits as Drug Firms Work It Out, TORONTO
STAR, Aug. 29, 2000, [ 3, available at 2000 WL 2539294. Viramune is a drug that
prevents mother-to-child transmission of the AIDS virus. See id.
179. See Albright Spotlights AIDS Fight, Hous. CHRON., Dec. 9, 2000, at 30,
available at 2000 WL 24533258. Flucanozole is used to treat meningitis and throat
inflammation of AIDS patients. See id.
180. See Bond, supra note 58, at 780 (quoting Love, J. Gore & Mbeki Commis-
sion and Compulsory Licensing Disputes with South Africa. Personal communica-
tion, Washington, D.C., April, 2, 1999). Critics also observed that the donation was
less than the $146 million paycheck of the company's CEO and that the announce-
ment came just two weeks before the World Health Assembly meeting in Geneva.
See id.
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is clear from grassroots efforts, NGO campaigns, and IGO initia-
tives. 181
Numerous efforts by IGOs and NGOs have been prominent
in the fight against AIDS. High-profile organizations, including
UNAIDS and Nobel Peace Prize winner Doctors Without Bor-
ders, bring international and scientific attention to the prob-
lem. 82 The United Nations Commission on Human Rights ap-
proved a resolution submitted by Brazil stating that access to
H1V/AIDS treatment is a fundamental aspect of the right to
physical and mental health.183 Recently, the United Nations
Special Session on HIV/AIDS issued a Declaration of Commit-
ment on HIV/AIDS, calling for national strategies and interna-
tional cooperation to disseminate AIDS awareness and preven-
tion. l' 4  The degree and intensity of attention from the
international community has given the AIDS crisis a place on
the agenda of nearly every nation.
The United States has a conflicted history when it comes to
protecting patent laws and promoting access to medicines. The
United States has already brought two developing nations be-
fore the WTO panel to seek stronger national patent laws and
compliance with TRIPs. 8 5 It has effectively used the threat of
trade sanctions to cow other nations into strengthening national
patent laws. 8 6 In addition, the United States was the sole coun-
try out of fifty-three nations to veto the UN Human Rights
Commission's declaration on access to HIV/AIDS treatment as a
fundamental right. 87 Despite this seemingly anti-access behav-
ior, the United States government appears increasingly inter-
ested in protecting and improving South Africa's access to
drugs. In the 106th Congress, Senators Feinstein and Feingold
introduced an amendment to the Africa Growth and Opportu-
181. See, e.g., Activists Highlight AIDS Toll During Annual Observance, supra
note 65; Razak, supra note 160; Woods, supra note 85.
182. See generally Accelerating Access to Care, Support, and Treatment,
UNAIDS, available at http:/ /www.unaids.org/acc access /accjcare-support/
newsbulletin2.html (last visited on Sept. 15, 2001).
183. See Gustavo Capdevila, Health: U.N. Rights Panel Favors Free Access to
AIDS Drugs, INTER PRESS SERVICE, Apr. 23, 2001, at 2001 WL 4803632.
184. See United Nations, Declaration of Commitment on HIVIAIDS, United Na-
tions Special Session on HIV/AIDS, I 37-57, (June 2001), available at
http://www.unaids.org/whatsnew/others/un-special/Declaration2706_en.htm (last
visited Aug. 2, 2001).
185. See supra notes 107-116 and accompanying text.
186. See supra notes 66-78 and accompanying text.
187. See Capdevila, supra note 183. The resolution was submitted by Brazil and
approved by fifty-two of fifty-three countries. See id.
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nity Act to increase access to generic AIDS drugs. 88 This
amendment was later struck from the final Africa Trade Con-
ference Report.189 However, the growing crisis and international
attention has changed attitudes over the course of just one year.
President Clinton's Executive Order protecting access to drugs
soon followed the deleted amendment.19 ° The order protects the
developing nations from retaliation and is a powerful shield for
South Africa because it broadens its options considerably.
Unlike Thailand, which was coerced into enacting stronger pat-
ent laws, South Africa no longer has the threat of trade sanc-
tions looming over its shoulder. Likewise, South Africa is safe
from India and Brazil's fate before the WTO dispute panel. The
Executive Order clears the air of any Special 301 or WTO
threats."' Thus, South Africa is free to enact affordable medi-
cine legislation, develop access-friendly policies, and make deci-
sions like the one to buy generic drugs from Cipla.
Legislators have continued their efforts to promote access to
vital medicines. Senators Dianne Feinstein from California and
Russ Feingold from Wisconsin continued their efforts to increase
access to medicines by introducing the Access to AIDS Treat-
ment Act of 2001, which would: 1) require World Health Organi-
zation and USAIDS to take the lead in the international organi-
zation of producing and distributing HIV/AIDS drugs; 2) permit
developing countries suffering an HIV/AIDS health care crisis to
use compulsory licensing or parallel importation consistent with
TRIPs; 3) authorize $25 million per year in grants to developing
countries to create and execute programs for improving health
care systems and the distribution of HIV/AIDS drugs; 4) create
a global database of HIV/AIDS drugs, including their price,
quality, and patent status; and 5) authorize $1 million per year
for loan repayment and deferment program for various health
professionals who provide HTV/AIDS treatment and care in de-
veloping nations. 192
The Affordable HIV/AIDS Medicines for Poor Countries Act
was introduced in the House of Representatives last March. It
188. See HIVIAIDS Drug Database, 44 BLUE SHEET, Mar. 21, 2001, at 2001 WL
7811097.
189. See id.
190. See Exec. Order 13155, supra note 90.
191. See id.
192. See Dianne Feinstein, Senators Feinstein and Feingold Introduce Legisla-
tion to Increase Access to HIVIAIDS Treatment in Developing Countries, Govern-
ment Press Release, Federal Document Clearing House (March 6, 2001), at 2001 WL
5420413.
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recognizes pricing policies and pricing practices of drug compa-
nies and also prohibits the USTR from challenging a country in
the WTO over its policies on access to HIV/AIDS drugs.193 Rep-
resentatives Barbara Lee and Jan Shakowsky introduced H.R.
1185, the Global Access to HIV/AIDS Medicines Act of 2001,
which codifies President Clinton's Executive Order 13155.194
Representative Joseph Crowley introduced the Global Health
Act of 2001, which earmarks an additional $1 billion to global
health programs, including a $275 million budget increase for
HIV/AIDS, calls for greater coordination between the govern-
ment health agencies, and increases funding for programs com-
bating infectious disease. 195 Other legislators are using eco-
nomic means to protect access to drugs. In May of 2001,
Representatives Waters and Sanders introduced H.R. 1690 to
amend the Export-Import Bank Act of 1945. This amendment
would prohibit the U.S. Export-Import Bank from assisting the
export of any good or service to or by a company challenging a
patent law or policy of a developing country that promotes ac-
cess to HIV/AIDS drugs. 196 Based on these actions, it seems
that South Africa has the ironic support of the United States in
its efforts to increase affordability and accessibility of HIV/AIDS
medicines.
CONCLUSION
South Africa's outlook for accessing affordable medicines is
fairly positive. South Africa's patent legislation should be safe
from trade retaliation or litigation because its provisions on
parallel importation and compulsory licensing are legal under
TRIPs. The provision providing for parallel importation is per-
missible under TRIPs because the agreement does not prohibit
this type of trade. Also, provisions that allow compulsory licens-
ing are legitimate under TRIPs exceptions provided for in the
agreement. South Africa should be able to follow through and
193. See Affordable HIV/AIDS Medicines for Poor Countries Act, H.R. 933, 107th
Cong. § 2 (2001).
194. See Barbara Lee, Decision to Drop Lawsuit Against South Africa Stresses
Importance of Legislation to Improve Access to Life Medication, Government Press
Release, Federal Document Clearing House (Apr. 19, 2001), available at 2001 WL
5421088.
195. See 147 CONG. REC. E476-05, (daily ed. Mar. 28, 2001) (statement of Rep.
Crowley).
196. See Export-Import Bank HIV/AIDS Medicines Access Promotion Act, H.R.
1690, 107th Cong. § 2 (2001).
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freely grant compulsory licenses because the HIV/AIDS crisis is
a national emergency, compulsory licenses are necessary to pro-
tect human life or health, and HIV/AIDS is seriously eroding
development in South Africa. Public relations guarantees that
South Africa will be protected from legal challenge over its pat-
ent laws; companies and governments are well aware of the pub-
lic condemnation that would swiftly follow such action. Public
relations also improve South Africa's situation by expanding its
pool of affordable drugs through discounted drug offers and do-
nations. Finally, international political and non-governmental
bodies are strongly supportive of opening up South Africa's ac-
cess to HIV/AIDS medicines. This support has even filtered
through to the United States government, where legislators are
making efforts to pass friendlier drug-access legislation. In
light of these factors, access to affordable medicines will likely
increase for the South African government, as well as for the
thousands of South African citizens waiting for medicines.
